-
BeOne Medicines Announces U.S FDA Approval for Tevimbra-Based Regimen for First-Line HER2+ GEA
NASDAQ: $ONC SAN CARLOS, Calif.–(BUSINESS WIRE) Aug 25, 2026 — BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics… Source: Read More